Finance

Lists
Why is ENGN up 5.70%?
Dive Deeper
ENGN:NASDAQ
enGene Therapeutics Inc
$2.41
+5.70%
(+0.13) 1D
$2.32
-3.78% (-0.091)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
$2.41
High
$2.51
Low
$2.17
Mkt. cap
161.51M
Avg. vol.
1.29M
Volume
3.72M
52-wk high
$12.25
52-wk low
$1.40
EPS
-$2.08
Beta
-0.24
Shares outstanding
67.02M
No. of employees
82
Open
$2.41
High
$2.51
Low
$2.17
Mkt. cap
161.51M
Avg. vol.
1.29M
Volume
3.72M
52-wk high
$12.25
52-wk low
$1.40
EPS
-$2.08
Beta
-0.24
Shares outstanding
67.02M
No. of employees
82
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteengene.com
Analyst ratings
Based on 6 analysts giving stock ratings to ENGN in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current $2.41
$6.00 (+148.96%)
Average
$4.20 (+74.27%)
Lowest
$2.00 (-17.01%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
11/12/2026
Lili (Aurélie) Nsongo
Leerink Partners
Buy
Upgraded
$5.00
+107.5%
11/13/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$4.00
+66%
11/12/2026
Allison Bratzel
Piper Sandler
Buy
Upgraded
$4.00
+66%
11/12/2026
Yanan Zhu
Wells Fargo
Buy
Upgraded
$6.00
+149%
11/12/2026
David Dai
UBS
Hold
Reiterated
$2.00
-17%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
$2.00
-17%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$4.00
+66%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
$21.50
+792.1%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
$21.50
+792.1%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
$21.50
+792.1%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
$28.00
+1,061.8%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Oct 2025
Jan 2026
Apr 2026
Jul 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31.72M
22.26M
22.20M
20.09M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.76M
8.93M
9.77M
13.92M
Operating expense
39.48M
31.18M
31.97M
34.01M
Total operating expenses
39.48M
31.18M
31.97M
34.01M
Operating income
-39.48M
-31.18M
-31.97M
-34.01M
Other non operating income
448.00K
-
-
-
EBT including unusual items
-38.38M
-29.75M
-30.23M
-32.50M
EBT excluding unusual items
-38.38M
-29.26M
-30.23M
-32.50M
Income tax expense
-497.00K
-
-
-
Effective tax rate
1.29%
-
-
-
Other operating expenses
-
-
-
-
Net income
-37.88M
-29.75M
-30.23M
-32.50M
Net profit margin
-
-
-
-
Earnings per share
-0.73
-0.44
-0.43
-0.47
Interest and investment income
1.98M
2.74M
2.66M
2.40M
Interest expense
-750.00K
-732.00K
-745.00K
-843.00K
Net interest expenses
1.22M
2.01M
1.92M
1.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-39.31M
-31.00M
-31.79M
-33.84M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps